What the trial was testing
The trial enrolled 399 patients with type 2 diabetes. The study was sponsored by Eli Lilly and Company and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
The once-weekly insulin caused 25% fewer low blood sugar episodes compared to daily insulin.
The lancet. Diabetes & endocrinology · 2023 · NCT03736785
These findings — that weekly insulin caused fewer dangerous blood sugar drops than daily insulin — were published in the The lancet. Diabetes & endocrinology and represent the headline result of the study.
Researchers tracked outcomes across 399 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with type 2 diabetes, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This treatment is still in testing and not yet FDA-approved. If you're on daily insulin and struggling with the routine, this research suggests a once-weekly option might work just as well with fewer lows. Talk to your doctor about whether you might qualify for a clinical trial testing this approach.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open type 2 diabetes trials
OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme
The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions.
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.